Antibiotic Treatment for Staphylococcus aureus (Including MRSA) Infections
For suspected MRSA infections, start empiric therapy with vancomycin or daptomycin, then narrow to cefazolin or an antistaphylococcal penicillin once methicillin-susceptible S. aureus (MSSA) is confirmed. 1
Treatment Algorithm Based on Clinical Setting
Outpatient Skin and Soft Tissue Infections (SSTI)
For purulent cellulitis or abscesses requiring antibiotics:
- First-line oral options for MRSA coverage: 2
- Clindamycin 300-450 mg PO three times daily (most versatile, covers both MRSA and streptococci)
- TMP-SMX 1-2 double-strength tablets twice daily (requires addition of amoxicillin if streptococcal coverage needed)
- Doxycycline 100 mg PO twice daily (add amoxicillin for streptococcal coverage)
- Linezolid 600 mg PO twice daily (expensive, reserve for resistant cases)
Duration: 5-10 days, adjusted based on clinical response 2
Key decision point: Distinguish purulent vs. nonpurulent cellulitis:
- Purulent cellulitis (drainage/exudate without drainable abscess): Empiric MRSA coverage required 2
- Nonpurulent cellulitis (no drainage/exudate): Start beta-lactam for streptococci; add MRSA coverage only if no response or systemic toxicity present 2
Hospitalized Patients with Complicated SSTI
Empiric IV therapy options: 2
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (first-line, A-I evidence)
- Daptomycin 4 mg/kg/dose IV once daily (A-I evidence)
- Linezolid 600 mg PO/IV twice daily (A-I evidence)
- Telavancin 10 mg/kg/dose IV once daily (A-I evidence)
- Clindamycin 600 mg IV/PO three times daily (only if local resistance <10%)
Duration: 7-14 days based on clinical response 2
Bacteremia and Serious Invasive Infections
Once susceptibilities are known:
For MSSA bacteremia:
- Cefazolin is preferred over vancomycin (superior outcomes demonstrated) 3, 1
- Alternative: Antistaphylococcal penicillin (nafcillin/oxacillin)
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (standard of care)
- Daptomycin 6 mg/kg/dose IV once daily (shown noninferiority to vancomycin; treatment success 44% vs 42%) 1
- Consider daptomycin for persistent bacteremia or vancomycin-resistant strains
Duration: 4-6 weeks for bacteremia with high-risk features (endocarditis, metastatic infection, persistent fever) 3
Pneumonia
MRSA pneumonia treatment: 2
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (A-II evidence)
- Linezolid 600 mg PO/IV twice daily (A-I evidence; may be superior to vancomycin in hospital-acquired pneumonia) 5, 6
- Clindamycin 600 mg three times daily (B-III evidence)
Important caveat: Daptomycin should NOT be used for pneumonia—it is inactivated by pulmonary surfactant 6
Pediatric Dosing Adjustments
- Vancomycin: 15 mg/kg/dose IV every 6 hours 2
- Clindamycin: 10-13 mg/kg/dose every 6-8 hours (max 40 mg/kg/day) 2
- Linezolid: 10 mg/kg/dose every 8 hours for <12 years; 600 mg twice daily for ≥12 years 2
- TMP-SMX: 4-6 mg/kg trimethoprim component every 12 hours 2
- Tetracyclines contraindicated in children <8 years 2
Critical Pitfalls to Avoid
Do NOT use rifampin as monotherapy or adjunctive therapy for SSTI—resistance develops rapidly 2
Simple abscesses: Incision and drainage is primary treatment; antibiotics only needed for: severe/extensive disease, multiple sites, rapid progression with cellulitis, systemic illness, immunosuppression, extremes of age, difficult-to-drain locations (face/hand/genitalia), septic phlebitis, or failed I&D 2
Vancomycin limitations: Emerging concerns about efficacy with less-susceptible strains and nephrotoxicity with high-dose therapy challenge its role as automatic first-line 6
Clindamycin use: Only appropriate when local resistance rates <10%; higher risk of C. difficile infection compared to other oral agents 2
TMP-SMX: Pregnancy category C/D—avoid in third trimester and infants <2 months 2
Emerging Evidence
Recent network meta-analyses suggest linezolid may have superior clinical and microbiological success rates compared to vancomycin for MRSA infections (RR 1.71; 95% CI 1.45-2.02), particularly in cSSSIs, cSSTIs, and pneumonia 7, 8. However, linezolid carries higher adverse reaction rates, particularly thrombocytopenia 7, 8. This positions linezolid as an important alternative when vancomycin fails or in pneumonia cases where it may be preferred 5.